lyophilised powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-31 and is reviewed periodically as new material appears.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | Reversed-phase HPLC with UV detection | Separates target peptide from truncated and oxidised forms |
| Identity confirmation | LC-MS or ESI-MS | Compares observed and calculated molecular ion |
| Primary degradation route | Methionine oxidation | Forms the sulfoxide; monitored as an early-eluting peak |
| Short-term storage | 2 to 8 degrees Celsius | Applies to working vials and reconstituted portions |
| Common synonyms | ACTH(4–10) analogue, MEHFPGP | Descriptive names used in laboratory catalogues |
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
In October 2022, 777 Partners bought a minority stake in Melbourne Victory FC of the Australian A-League Men for AU$8.7 million. The following January, the club's shareholders voted in favor of allowing 777 Partners to secure up to 70% over the next five years, in exchange for AU$30 million in investment. The voluntary administration of 777 Partners' Australian airline Bonza in 2024 meant that Melbourne Victory were sponsored by AIA Group for the playoffs that year, before a long-term deal with Turkish Airlines could begin in 2025.
== Synthesis == Immunoliposomes are created when antibodies are conjugated to liposomes. One way to do this is through covalent bonds between the antibody (or its fragment) and the lipid. Another way is through chemical modification of antibodies so they have a higher affinity for the liposome. "In general, the conjugation methodology is based on three main reactions; a reaction between activated carboxyl groups and amino groups which yields an amide bond, a reaction between pyridyl dithiols and thiols which yields disulfide bonds, and a reaction between maleimide derivatives and thiols, which yields thioether bonds."
Supelco is the chromatography products branch of Sigma-Aldrich. It provides chromatography columns and related tools for environmental, government, food and beverage, pharmaceutical, biotechnology, medical and chemical laboratories; sample preparation products and chemical reference standards.
=== In media === In the Stephen King short story collection Night Shift, the final story of the book, "The Woman in the Room", tells a tale in which the main character contemplates and then finally performs a mercy killing using a drug called "Darvon Complex". In his 1976 song "My Head Hurts My Feet Stink and I Don't Love Jesus" Jimmy Buffett references taking a Darvon to relieve his hangover.
Sources: en.wikipedia.org
Phosphofructokinase is an important control point in the glycolytic pathway, since it is one of the irreversible steps and has key allosteric effectors, AMP and fructose 2,6-bisphosphate (F2,6BP). F2,6BP is a very potent activator of phosphofructokinase (PFK-1) that is synthesized when F6P is phosphorylated by a second phosphofructokinase (PFK2). In the liver, when blood sugar is low and glucagon elevates cAMP, PFK2 is phosphorylated by protein kinase A. The phosphorylation inactivates PFK2, and another domain on this protein becomes active as fructose bisphosphatase-2, which converts F2,6BP back to F6P. Both glucagon and epinephrine cause high levels of cAMP in the liver. The result of lower levels of liver F2,6BP is a decrease in activity of phosphofructokinase and an increase in activity of fructose 1,6-bisphosphatase, so that gluconeogenesis (in essence, "glycolysis in reverse") is favored. This is consistent with the role of the liver in such situations, since the response of the liver to these hormones is to release glucose to the blood. ATP competes with AMP for the allosteric effector site on the PFK enzyme. ATP concentrations in cells are much higher than those of AMP, typically 100-fold higher, but the concentration of ATP does not change more than about 10% under physiological conditions, whereas a 10% drop in ATP results in a 6-fold increase in AMP. Thus, the relevance of ATP as an allosteric effector is questionable. An increase in AMP is a consequence of a decrease in energy charge in the cell.
== History == Between 1936 and 1940, Japanese chemist and lichenologist Yasuhiko Asahina published a series of papers in the Journal of Japanese Botany detailing the microcrystallization technique. This simple and rapid method allowed for the identification of major metabolites in hundreds of lichen species, contributing significantly to taxonomic research. The technique was introduced to western lichenologists in a 1943 publication by Alexander Evans, and was used regularly until more advanced techniques such as thin-layer chromatography and high-performance liquid chromatography were introduced and integrated into laboratories. Decades of research on the secondary metabolites of lichens culminated in the publication of Identification of Lichen Substances, a 1996 work by Siegfried Huneck and Isao Yoshimura, that summarized analytical data for hundreds of lichen molecules, including images of microcrystals. Ultimately, the microcrystallization method had limitations, as it was unable to detect minor components or analyze complex mixtures of lichen substances. Despite these drawbacks, microcrystallization played a crucial role in the study of correlations between lichen chemistry, morphology, and geographic distribution.
==== Alternative binding mechanisms ==== The LFT principle works with any collection of molecules that bind to each other with high affinity, so long as some of them can be immobilized to the gold nanoparticles and the test line respectively. For example:
Sources: en.wikipedia.org
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.
Oxidation of the methionine residue to the sulfoxide is a frequently reported change, and it usually appears as an earlier-eluting peak in reversed-phase chromatography. Backbone hydrolysis products can also accumulate in aqueous solution.
Liquid chromatography coupled with mass spectrometry is the usual approach, because the observed molecular ion can be compared with a calculated mass of about 813.9 Da. Retention time alone does not establish identity.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.